Cargando…

Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report

BACKGROUND: Both large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are high-grade neuroendocrine tumors of lung in classification. Combined LCNEC and combined SCLC may comprise up to 25% of the resected cases. However, co-existence of LCNEC and SCLC in lung accompanied...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Ling, Li, Jingyuan, Ye, Ting, Wang, Wenjun, Li, Yuying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372195/
https://www.ncbi.nlm.nih.gov/pubmed/35966332
http://dx.doi.org/10.21037/tcr-21-2793
_version_ 1784767326936104960
author Ai, Ling
Li, Jingyuan
Ye, Ting
Wang, Wenjun
Li, Yuying
author_facet Ai, Ling
Li, Jingyuan
Ye, Ting
Wang, Wenjun
Li, Yuying
author_sort Ai, Ling
collection PubMed
description BACKGROUND: Both large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are high-grade neuroendocrine tumors of lung in classification. Combined LCNEC and combined SCLC may comprise up to 25% of the resected cases. However, co-existence of LCNEC and SCLC in lung accompanied with combined LCNEC in extrapulmonary metastatic sites is infrequent. CASE DESCRIPTION: In this paper, we report a 58-year-old male with cough, back pain and increased sputum. He was diagnosed as LCNEC and SCLC in his lung successively. His tumor gradually progressed and combined LCNEC was then diagnosed in his cervical lymph node. Regimens of chemotherapy were accordingly adjusted several times, but his lesions were not relieved and he finally died. CONCLUSIONS: Both LCNEC and SCLC have high aggressiveness. Some patients may have limited curative effect and poor prognosis when treated with chemotherapy even in combination with immune checkpoint inhibitors. Combined LCNEC may occur in extrapulmonary sites of some patients when the tumor progresses. Timely radiological evaluations are essential to identify changes of pulmonary and extrapulmonary lesions. Histopathological results including morphological features of malignant cells and immunohistochemical features of diseased tissues are more indispensable in establishing a confident diagnosis of lung neuroendocrine tumor and judging corresponding cellular types.
format Online
Article
Text
id pubmed-9372195
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-93721952022-08-13 Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report Ai, Ling Li, Jingyuan Ye, Ting Wang, Wenjun Li, Yuying Transl Cancer Res Case Report BACKGROUND: Both large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are high-grade neuroendocrine tumors of lung in classification. Combined LCNEC and combined SCLC may comprise up to 25% of the resected cases. However, co-existence of LCNEC and SCLC in lung accompanied with combined LCNEC in extrapulmonary metastatic sites is infrequent. CASE DESCRIPTION: In this paper, we report a 58-year-old male with cough, back pain and increased sputum. He was diagnosed as LCNEC and SCLC in his lung successively. His tumor gradually progressed and combined LCNEC was then diagnosed in his cervical lymph node. Regimens of chemotherapy were accordingly adjusted several times, but his lesions were not relieved and he finally died. CONCLUSIONS: Both LCNEC and SCLC have high aggressiveness. Some patients may have limited curative effect and poor prognosis when treated with chemotherapy even in combination with immune checkpoint inhibitors. Combined LCNEC may occur in extrapulmonary sites of some patients when the tumor progresses. Timely radiological evaluations are essential to identify changes of pulmonary and extrapulmonary lesions. Histopathological results including morphological features of malignant cells and immunohistochemical features of diseased tissues are more indispensable in establishing a confident diagnosis of lung neuroendocrine tumor and judging corresponding cellular types. AME Publishing Company 2022-07 /pmc/articles/PMC9372195/ /pubmed/35966332 http://dx.doi.org/10.21037/tcr-21-2793 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Case Report
Ai, Ling
Li, Jingyuan
Ye, Ting
Wang, Wenjun
Li, Yuying
Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report
title Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report
title_full Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report
title_fullStr Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report
title_full_unstemmed Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report
title_short Progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report
title_sort progressive neuroendocrine tumor of lung with combined categories in metastatic site: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372195/
https://www.ncbi.nlm.nih.gov/pubmed/35966332
http://dx.doi.org/10.21037/tcr-21-2793
work_keys_str_mv AT ailing progressiveneuroendocrinetumoroflungwithcombinedcategoriesinmetastaticsiteacasereport
AT lijingyuan progressiveneuroendocrinetumoroflungwithcombinedcategoriesinmetastaticsiteacasereport
AT yeting progressiveneuroendocrinetumoroflungwithcombinedcategoriesinmetastaticsiteacasereport
AT wangwenjun progressiveneuroendocrinetumoroflungwithcombinedcategoriesinmetastaticsiteacasereport
AT liyuying progressiveneuroendocrinetumoroflungwithcombinedcategoriesinmetastaticsiteacasereport